Sponsors (25)
The bill strengthens antimicrobial R&D, access, stewardship, and national preparedness—potentially improving patient outcomes and readiness—but does so at increased federal cost and with risks of higher drug prices, regulatory burdens, and allocation tensions during shortages.
Patients (including those with chronic conditions), hospitals, and clinicians will gain greater access to effective antimicrobials plus new tools and programs to prevent and treat drug‑resistant infections, improving patient outcomes and reducing resistant infections.
Scientists and researchers (and ultimately patients) will receive new federal support for antimicrobial research and development, accelerating development of new antibiotics and diagnostics.
Hospitals, public‑health systems, and the military will benefit from stronger national preparedness—making antibiotics and related therapies more available during pandemics, biodefense events, or to protect service members' health and readiness.
Taxpayers could face increased federal spending to support drug R&D and market access programs, raising government costs if not offset.
Patients may face higher drug prices if the measures favor private firms or do not preserve drug‑price protections, increasing out‑of‑pocket costs for those who need antimicrobials.
Clinicians, hospitals, and state public‑health agencies could incur new regulatory and administrative burdens from expanded programs and procurement processes.
Based on analysis of 3 sections of legislative text.
Appends a new Public Health Service provision to promote antimicrobial innovation, access, stewardship, preparedness, and defense readiness; implementation details are not provided in excerpt.
Official title: To amend the Public Health Service Act to establish a program to develop innovative antimicrobial drugs targeting the most challenging pathogens and most threatening infections, and for other purposes.
Introduced February 4, 2026 by Buddy Carter · Last progress February 4, 2026
Creates a new Public Health Service authority to support development and sustained availability of antimicrobials through a program called "Developing antimicrobial innovations." The law frames goals to stimulate research and market access for lifesaving antimicrobial medicines, ensure their appropriate clinical use, strengthen health system preparedness, and support national defense needs. The text provided appends a new provision to Title III of the Public Health Service Act but does not include the inserted provision's text, so program details, funding levels, timelines, and implementation rules are not available from this excerpt.